Apr 08, 2019
Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute
Apr 04, 2019
MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.
Mar 26, 2019
Eiger BioPharmaceuticals to Participate in Conferences in April
Mar 05, 2019
MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D Infections
Feb 20, 2019
Abbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine(TM) HBsAg 2, to Accelerate Hepatitis B Care
Feb 06, 2019
Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
Jan 16, 2019
CME Outfitters Launches New Interactive Medical Simulation on Hepatitis B Virus
Dec 20, 2018
Cepheid Receives CE-IVD Clearance for Xpert® HBV Viral Load
Dec 18, 2018
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection
Dec 17, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection
Dec 14, 2018
Global Hepatitis Test Solution/Diagnosis Market to 2023 with Roche, Abbott Laboratories, Bio-Rad, Siemens, DiaSorin, QIAGEN, Danaher, bioMrieux, and Grifols Dominating
Nov 29, 2018
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications
Nov 27, 2018
Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure
Nov 20, 2018
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
Nov 02, 2018
China Entecavir Investigation Market Report, 2018-2022 - Market Size, Competitive Landscape, Price by Manufacturer & Market Outlook
Oct 31, 2018
TARGET PharmaSolutions® Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B
Oct 29, 2018
MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta
Oct 23, 2018
MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D Infections
Oct 17, 2018
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
Oct 04, 2018
Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection